Stockscreener 앱 받기
120.05
2.45%
2.87
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - Eagle-Tribune
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Brings Sleep Disorder and Cancer Treatment Updates to BofA Healthcare Conference - Stock Titan
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings - The Globe and Mail
PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy - insights.citeline.com
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
3 Unconventional Cannabis Stocks to Watch in 2025 - Yahoo Finance
With A 14% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock? - Yahoo Finance
Antisense Oligonucleotides Market Trends, Growth - openPR.com
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead - Yahoo Finance
3 Reasons To Sell JAZZ And 1 Stock To Buy Instead - Barchart.com
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Gains European Advisory Support for Zanidatamab | JAZZ Stock News - GuruFocus
PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs - Seeking Alpha
Jazz Pharmaceuticals Receives Positive EMA Panel Opinion for Zanidatamab to Treat Biliary Tract Cancer - marketscreener.com
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma - Placera.se
Major Cancer Breakthrough: New Phase 3 Data Reveals Significant Survival Benefits in Lung Cancer Treatment - Stock Titan
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 - PR Newswire UK
TD Cowen maintains Jazz stock Buy rating, $100 target By Investing.com - Investing.com UK
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Canada Pension Plan Investment Board Purchases 8,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
JAZZ Vs. HRMY: Which Neuroscience Drugmaker Is The Stronger Play? - Barchart.com
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Yahoo Finance
Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug - Bloomberg Law News
JAZZ vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Yahoo Finance
Is Jazz Pharmaceuticals A Top Cannabis Investment For 2025? - Barchart.com
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? - Zacks Investment Research
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com
Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK
Where Jazz Pharmaceuticals Stands With Analysts - Benzinga
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Nasdaq
Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN
Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Settles Antitrust Claims for $145M - GuruFocus
Jazz Pharma stock slips after $145M antitrust deal (JAZZ) - Seeking Alpha
0.47%
2.63%
자본화:
|
볼륨(24시간):